Company intelligence / Profile preview
AmideBio
Louisville, Colorado, United Statesamidebio.com ↗
- Ownership
- Private
- Employees
- ~8
- Development stage
- Preclinical
01
Overview
AmideBio has developed a proprietary platform for the in-silico design and efficient synthesis of novel peptides targeting metabolic diseases. Its pipeline consists of preclinical drug candidates with a focus on diabetes and related disorders. The company aims to license its programs at or before the IND stage; no clinical results have been reported yet.
- Therapeutic areas
- Metabolic DisordersEndocrinology
- Modalities
- Peptides
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
National Institute of Diabetes and Digestive and Kidney Diseases / NIH funding partners/investors
Beyond the preview
Go deeper on AmideBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AmideBio.